All Industries

The $3 Trillion Market Disruption is here: Axon’s Groundbreaking Decentralized Fiat-Crypto Exchange is Set to Revolutionize Fintech

Deutsche Bank AG

Axon, the pioneer behind the world’s first decentralised fiat<>crypto exchange (DEX), has officially launched its pioneering mobile platform, now available on the Apple App Store and Google Play. Following a successful $2 million funding round, Axon is leading the charge in financial innovation with a full spectrum of seamless non-custodial fiat<>crypto services. You can now Buy, Sell, Borrow, Earn, and Swap crypto instantly with unparalleled transparency, trust and ultra-low fees. The highly anticipated non-custodial fiat<>crypto exchange, introduced by Axon, is now live, finally bridging the gap between traditional finance and crypto. Axon has achieved an unprecedented milestone in the decentralised finance (DeFi) landscape. For the first time in history, any fiat or crypto liquidity provider will receive a pro-rata cut from the fiat<>crypto trades done through the Axon protocol. Axon’s platform empowers both private and institutional liquidity providers to participate directly in its decentralized fiat<>crypto exchange. The company has introduced a groundbreaking blockchain primitive that addresses one of the final missing pieces in the DeFi ecosystem. While Uniswap revolutionised decentralised swaps and AAVE dominated crypto-backed lending, Axon delivers the final essential building block: a non-custodial fiat<>crypto DEX poised to transform how Web3 businesses and users interact with traditional finance. “Axon is redefining the standards of trust, inclusivity and efficiency. Axon is empowering the entire crypto community to actively and securely participate in disrupting the $3 trillion fiat<>crypto market. This market was once monopolised by a select few centralised financial (CeFi) players. The era of centralised dominance is over, and Axon is the spearhead of this transformative tide,” asserted George Stoyanov, CEO and co-founder of Axon. Axon’s patent pending architecture, connected to over 14,000 banks across the USA and Europe and compatible with more than 330 wallets, is redefining the market. The time for transparent, quick, and low-risk fiat<>crypto trading has arrived, and Axon is leading the charge by finally providing a solution for retail, B2B and institutional investors. About Axon Founded in 2022, Axon brings the world’s first fiat<>crypto decentralised exchange. The company is a distinguished winner of the Avalanche Codebase program, recognised for providing critical infrastructure for non-custodial transactions. The protocol has already been integrated with leading DeFi platforms such as BENQI, GoGoPool, and AAVE. Axon’s infrastructure has undergone rigorous independent audits by PALADIN blockchain security and Weichain, further solidifying its position as a trailblazer in the industry. Contact Details Axon Galin Mihaylov pr@axonfinance.com

September 11, 2024 07:28 PM Eastern Daylight Time

Image

Tesla BioHealing and Cell Biotechnology Co., Ltd. Forge Strategic Partnership to Transform Stem Cell Therapies

Pinion Newswire

Tesla BioHealing-PA, LLC, a leader in biophoton life force technology, and Cell Biotechnology Co., Ltd, an innovator in stem cell transplantation, have entered a strategic collaboration to revolutionize the development and delivery of stem cell therapies. This partnership, effective September 9, 2024, unites the companies’ groundbreaking technologies to significantly enhance patient outcomes by empowering autologous stem cell amplification and ensuring immediate availability of large numbers of stem cells. A Revolutionary Alliance Tesla BioHealing, known for its pioneering biophoton technology that boosts life force energy to empower autologous stem cell production, will work alongside Cell Biotechnology, an industry leader in stem cell transplantation, to create integrated stem cell therapy solutions. This collaboration will blend Tesla BioHealing’s proprietary technology with Cell Biotechnology’s expertise, aiming to deliver cutting-edge, more effective, and accessible treatments to patients globally. Pooling Expertise to Improve Patient Outcomes The partnership will focus on joint research, development, and commercialization of enhanced autologous stem cell amplification and transplantation solutions. By sharing proprietary information, research data, and technological expertise, both companies aim to expedite product development, clinical trials, regulatory approvals, and ultimately improve patient outcomes through more effective stem cell therapies. “Tesla BioHealing is thrilled to collaborate with Cell Biotechnology to combine our innovative biophoton technology with their advanced stem cell transplantation techniques,” said Dr. James Liu, CEO of Tesla BioHealing. “This partnership will enable us to broaden the reach of our technology, significantly impacting our R&D and transforming the future of stem cell treatments.” Dr. Taihua Wang, president of Cell Biotechnology, echoed this sentiment, saying, “We are excited to join forces with Tesla BioHealing in this groundbreaking initiative. Combining our stem cell expertise with their cutting-edge biophoton technology opens up new possibilities for advancing stem cell therapies, bringing life-changing treatments to more patients in the near future.” Commercialization and Global Impact Under the agreement, both companies will collaborate on clinical development and commercialization initiatives, including joint research, co-marketing, co-branding, and sales strategies. This strategic partnership has the potential to reshape the stem cell therapy landscape, making advanced, effective treatments more widely available to patients around the world. With a shared vision for transforming stem cell therapies, Tesla BioHealing and Cell Biotechnology Co., Ltd. are positioned to make a lasting impact on the future of regenerative medicine. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. These statements include, but are not limited to, the potential benefits of Tesla BioHealing® and Cell Biotechnology products. Factors that could cause actual results to differ materially include risks that clinical development activities may be delayed or unsuccessful, that products may not be approved or commercially viable and that regulatory decisions may be unfavourable. Tesla BioHealing Inc. and Cell Biotechnology disclaim any obligation to update these statements after the date hereof except as required by law. About Tesla BioHealing-PA, LLC Based in Butler, PA, Tesla BioHealing is a leader in biophoton technology, developing innovative solutions to enhance life force energy. The company’s technologies are designed to provide safe, effective, and easy-to-use therapies, including stem cell empowerment and other health-promoting solutions. About Cell Biotechnology Co., Ltd. Headquartered in Vaughan, Ontario with several branches in Southeast Asia, Cell Biotechnology Co., Ltd. specializes in advanced stem cell transplantation technology. With a focus on improving patient outcomes through innovative cellular therapies, the company is dedicated to advancing the field of regenerative medicine. For media inquiries, please contact: Tesla BioHealing-PA, LLC Suzanne Street, MBA Director, Public Relations Email: Suzanne.street@teslabiohealing.com Phone: 302-265-2213 Cell Biotechnology Co., Ltd. Xenia Wang, MS, MBA Manager, Public Relations Email: xeniawang@icloud.com Phone: 647-929-6315 Contact Details Tesla BioHealing-PA, LLC Suzanne Street +1 302-265-2213 Suzanne.street@teslabiohealing.com Company Website https://www.teslabiohealing.com/

September 11, 2024 07:14 PM Eastern Daylight Time

Emmy-Winning Journalist Mercedes Soler Discusses the Power of Radio for Hispanic Marketers in a Special Noticias Newswire Interview

Noticias Newswire

As Hispanic Heritage Month kicks off, Noticias Newswire is proud to present an exclusive, documentary-style interview with Emmy Award-winning journalist Mercedes Soler. In this in-depth conversation, Soler shares her insights on why radio remains one of the most powerful media for reaching and engaging Hispanic audiences—a timely discussion during this month celebrating the achievements and contributions of the Hispanic community. In this exclusive interview, Bill Gato, CEO of Noticias Newswire and co-editor of Hispanic PR Blog, speaks with Soler about her journey from broadcast journalism to radio entrepreneurship. Together with her husband, Tomás Martínez, Soler co-founded Solmart Media in 2014, a network of seven Spanish-language radio stations that serve Southwest and Central Florida, reaching over 1.5 million listeners. A career in media: From TV to radio pioneer Soler rose to prominence as a founding anchor of Univision’s groundbreaking news show, Primer Impacto, where she spent two decades delivering hard-hitting journalism. She later transitioned to CNN en Español, further solidifying her reputation as one of the most trusted names in Spanish-language television. Today, Soler continues to blaze trails as a radio entrepreneur with Solmart Media, where she and her husband are dedicated to connecting with the growing Hispanic market through the power of radio. Not your typical talking-head video This 54-minute interview is more than just a standard Zoom-style chat. The documentary-style production includes dynamic b-roll footage, featuring photos, videos, maps, and animations that vividly illustrate Soler’s insights. From exploring radio’s resilience in the digital age to highlighting the unique community engagement that radio offers, these visual elements create an immersive experience for viewers. According to Nielsen, 97% of U.S. Hispanics still tune into radio on a monthly basis—making it the most widely consumed media among this demographic, surpassing even TV and digital platforms. “There’s no other media that people go back to, that people trust, that holds your hand, that becomes your friend on a daily basis, like radio,” Soler says. “Not television, not cable, not streaming, not phone, not Spotify, not social media. Radio is not only not dead. Radio is the strongest force in media today.” Perfect timing for Hispanic Heritage Month As marketers and PR professionals look for ways to connect with the rapidly growing Hispanic market, this interview offers a timely reminder of radio’s enduring cultural relevance. Hispanic Heritage Month celebrates the rich history, culture, and contributions of Hispanics in the U.S., and Soler’s story—of entrepreneurship, media innovation, and cultural leadership—embodies that spirit. Key takeaways for PR pros and marketers: The surprising ways radio outpaces other media in reaching Hispanic audiences. How Soler and her husband built Solmart Media from the ground up to serve the Southwest and Central Florida Hispanic communities. Why understanding the Regional Mexican music format is key for marketers targeting U.S. Hispanics. How press releases and authentic media pitches still play a role in Hispanic radio. Watch the full interview The full-length interview offers invaluable lessons for Hispanic PR professionals, entrepreneurs, and marketers alike. To watch the video and gain unique insights into radio’s powerful role in Hispanic marketing, click here: https://www.youtube.com/watch?v=EYtAmbW6eYI And to read the full transcript, click https://www.hispanicprblog.com/mercedes-soler-interview-transcript/ About Noticias Newswire Noticias Newswire is the only Latino-owned and operated press release distribution service focused on the U.S. Hispanic market. With a mission to empower Hispanic and multicultural communicators, Noticias Newswire offers comprehensive services for reaching the fastest-growing market in the U.S. To learn more, visit www.noticiasnewswire.com About Hispanic PR Blog Hispanic PR Blog is a trade publication and resource dedicated to helping Hispanic and multicultural public relations professionals navigate the latest trends, insights, and best practices in the industry. Co-edited by Noticias Newswire CEO Bill Gato, the blog offers expert advice, interviews, and in-depth coverage of the rapidly evolving Hispanic marketing and PR landscape. For more information, visit www.hispanicprblog.com. Contact Details Noticias Newswire Bill Gato +1 305-815-4567 bill@noticiasnewswire.com

September 11, 2024 02:42 PM Eastern Daylight Time

Image

CollisionRight Reaches 100 Collision Repair Shops

CollisionRight

CollisionRight LLC, a leading regional multi-shop collision repair operator, today announced the acquisition of its 100th shop. The milestone was reached within four years of the company’s founding, culminating in the rapid implementation of its initial market-entry campaign and setting the stage for an equally aggressive growth strategy that aims to increase CollisionRight’s footprint threefold over a five-year span. CollisionRight has reached its 100th-location milestone through the three-shop acquisition of Tripp’s Collision in Michigan. As with each of CollisionRight’s 41 acquisitions to date, Tripp’s will continue to do business under its market-leading local brand while benefiting from the support and efficiency of a unified, large-scale organization. All of CollisionRight’s locations are corporate-owned and run under a common operating system of management, technology, back-office support, and partnerships with insurance carriers and vendors. “Acquiring our 100th store in just a few years is a testament to the hard work and dedication of our remarkable team. It underscores the value that embracing the history of established and trusted collision repair brands can bring,” said Rich Harrison, CEO of CollisionRight. “Driven by our mission to provide exceptional customer service and create the best possible place to work, our team will continue to pursue rapid growth into the coming years.” Having reached the 100-shop milestone, CollisionRight intends to both increase its presence within the 10 states it currently serves and expand its footprint into numerous additional markets. Through strategic acquisitions of local market leaders like Tripp’s—as well as organic growth via insurance-carrier relationships, supply chain optimization, and calibration services—CollisionRight expects to triple its revenue within the next five years. About CollisionRight Headquartered in Columbus, Ohio, CollisionRight provides state-of-the-art collision repair services at 100 corporate-owned locations across 10 states: Illinois, Indiana, Kentucky, Maryland, Michigan, Ohio, Pennsylvania, Tennessee, West Virginia, and Wisconsin. Their team of more than 1,500 collision repair professionals puts more than 90,000 vehicles back on the road each year with a single priority in mind: Getting you back to GO. Every location operates under an established brand that has earned the trust of its local community through decades of prioritizing complete customer satisfaction and convenience. For more information about CollisionRight, or to contact your neighborhood collision repair shop, please visit www.CollisionRight.com. Note to the editor: the company logo, a high-resolution headshot of Rich Harrison, and a copy of the map illustrating CollisionRight’s geographical presence can be found at this link. Contact Details Razor Sharp PR Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website http://www.collisionright.com/

September 11, 2024 10:00 AM Eastern Daylight Time

Image

Now Four Years In, Here's How News Direct Leapfrogged the Legacy Newswire Industry

News Direct

In business parlance, the term “Leapfrog” refers to “ a strategy that involves making a significant change or innovation that goes beyond what is expected or incremental. The goal is to improve a position by either skipping stages or taking an alternative path to achieve a desired outcome”*. *Google AI Overview News Direct represents the latter of those two paths. Founded in 2020 by former Business Wire president, Gregg Castano, and owing to his 32+ year career with the Berkshire Hathaway subsidiary, News Direct enjoyed a head start unlike most other “challengers” to the established newswire industry order that also includes PR Newswire and Globe Newswire. Castano leveraged the vast industry knowledge and expertise accumulated across those three plus decades and combined it with a forward-looking vision brought to life with a state-of-the-art, custom-written tech stack sitting atop a cloud infrastructure. The result is what can best be described as a “Next-Gen” news and content distribution platform ideally suited for a 21 st -Century communications ecosystem. News Direct has either vastly improved or completely replaced virtually everything about the legacy newswire model, which Castano believed needed to more strongly embrace and adopt the leading-edge digital technologies that enable the user experience to be modernized and enriched. The features and functions of News Direct are in many ways unrecognizable from traditional wires, with the notable exception of their comprehensive distribution footprint, which is identical to the “Big 3”. Castano stated, “I felt strongly that for the newswire model to be sustainable, remain relevant and to grow, it needed to evolve. But more quickly than the classic interpretation of evolution, which suggests a slow, steady pace. Rapid evolution, I suppose, is what I envisioned, although at some point that becomes revolution. That’s a term I hesitate to use because it’s a bit shopworn and can seem hyperbolic, but there is no doubt that News Direct has changed the game in a big way.” Among the ways in which News Direct has upended and disrupted the traditional newswire model, highlights include: Cutting-Edge Technology: News Direct is built atop a modern, digital cloud infrastructure with a software stack custom-written to precise specifications that perfectly align with today’s communications landscape. Direct-to-SEO Optimization: The platform is engineered to automatically enhance news releases for search engines, ensuring greater visibility and reach. Multimedia Integration: Videos, images, and other rich media are easily incorporated into news releases to stimulate greater engagement – or can be sent as independent assets, no release required. This is a feature unique to the industry. User-Friendly Interface: The workflow is intuitive and designed for speed, efficiency and seamless collaboration, allowing users to create, review and distribute releases in minutes, rather than waiting for remote editors to “process” content. Greater Control and Flexibility: With News Direct, the user maintains complete control over their content throughout the distribution workflow. With no “middleman” editors, the distribution process can be directly managed end-to-end, ensuring that the news reaches the target audience without unnecessary delays, or the security risks of relying on intermediaries. Real-Time Analytics: Customers get instant insights into how their news is performing with real-time analytics that are retrievable on-demand from within the customer interface. Transparent, Cost-Effective Pricing: News Direct offers straightforward flat-rates with no word count limits, no fluctuating, geographically tiered pricing and no opaque hidden upcharges for things such as logos or trade media. Customers know exactly what they’re paying with a pricing model designed to be highly cost-effective and flat rates that make budgeting simple, easy and transparent, a particular advantage for high frequency users. No Distribution Trade-Offs: The News Direct distribution network is identical to that of legacy services, providing a superior user-experience without sacrificing comprehensive reach. Leadership and Industry Expertise: Founder and CEO Castano’s deep understanding of the market and vision for the future of news distribution that has been gained over a 40-year career is embedded into every aspect of News Direct. This wealth of expertise uniquely positions News Direct to meet the needs of modern communicators. News Direct was designed to be thoroughly modern, streamlined and user-friendly, offering unprecedented value, flexibility, and efficiency. The company is committed to helping communications professionals achieve their media outreach goals by meeting the demands they face in today’s fast-paced digital environment. About News Direct News Direct is a technology-driven content distribution and amplification platform for PR, IR, corporate communications and marketing professionals. Our automated platform delivers a completely reimagined, modernized user experience for newswire users that has reshaped the industry landscape. Additionally, the company has expanded its offerings to include an array of technology-enhanced message amplification tools ranging from sponsored content to podcasting products, all from a single online destination. Contact Details News Direct Corp. Media at News Direct +1 917-698-4131 media@newsdirect.com Company Website http://www.newsdirect.com

September 11, 2024 09:07 AM Eastern Daylight Time

Image

Kevel and Placements.io Announce Strategic Partnership to Address Unique Challenges in Retail Media

Kevel

Kevel, the API-first ad serving company for building custom, in-house ad platforms, and Placements.io, the leading revenue management platform for media companies, today announced a strategic partnership that will empower retailers and ecommerce brands to seamlessly manage, optimize and scale their retail media networks with unparalleled flexibility and precision. The partnership will integrate Kevel’s state-of-the-art Retail Media Cloud™ solution with Placements.io revenue management system. With this unified platform, retailers can manage, monetize and scale their ad inventory effectively in-house, which will help to maximize return on ad spend and drive more significant results from retail media investments. “At Kevel, we’re committed to providing our clients with the tools they need to succeed and scale their retail media networks,” commented James Avery, CEO of Kevel. “This partnership is a no-brainer for us - we are aligned with Placements.io in our relentless drive to make the internet a better place. Now, we can extend our capabilities even further to offer a more comprehensive solution that meets the complex needs of our retail and ecommerce customers.” As retail media continues to grow at an unprecedented rate, the ability to efficiently manage ad inventory, optimize campaigns, and maximize revenue while maintaining control of data and reporting has become crucial for retailers. “This partnership can help unlock revenue opportunities for retailers, ecommerce and media companies,” said Edwin Fu, Founder and CEO of Placements.io. “By bringing together two powerful platforms, retailers can achieve their goals with greater accuracy and efficiency.” By integrating Kevel’s cutting-edge API infrastructure with Placements.io’s robust order and billing management capabilities, this partnership aims to provide a solution that unifies processes and data across ad operations, sales, and finance to show the true value of advertising and address the unique challenges of the retail media landscape. Key Benefits of the Partnership: Enhanced Customization: Retailers can now build fully-customized ad platforms, streamline operations, and take advantage of advanced revenue management tools. Seamless Integration: Combining Kevel and Placements.io’s tech on one unified platform will help retailers manage and monetize their ad inventory more effectively. Scalable Solutions: Both platforms are built to scale, allowing retailers to expand their retail media networks without the limitation of traditional black-box ad tech solutions. Improved ROI: The collaboration will help retailers and ecommerce brands maximize return on ad spend, driving more significant results from their retail media investments. This partnership underscores both companies’ commitment to raising the bar within ad tech and retail media. By joining forces, Kevel and Placements.io are at the forefront of empowering today’s modern retailers to build custom, in-house, privacy-first, revenue-generating ad platforms that can adapt to the rapidly changing digital advertising landscape. For more information about the partnership and how it can benefit your business, please visit Kevel.com and Placements.io. About Kevel Kevel is powering innovative, flexible ad tech infrastructure APIs that fuel its Retail Media Cloud™. This unique offering is the only API-based solution for in-housing retail media technology that enables multi-brand retailers to differentiate based on their unique brand, improving shopper experience while maintaining total control of their first-party data.Kevel believes that every digital retailer should have the capability to build and scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Delivery Hero, Sonae, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media networks with Kevel. The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com About Placements.io Placements.io was founded in 2014 to provide a more modern platform for companies buying and selling digital-focused, omnichannel advertising. Placements.io powers over $12B in annual ad revenue for publishers, broadcasters, OTT/CTV companies, retailers, and emerging media companies. Placements.io has offices across the U.S. and in London, Singapore, and Taiwan. Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com Placements.io Lindsey Bradshaw lindseyb@placements.io

September 11, 2024 09:00 AM Eastern Daylight Time

Global Crypto Brokerage Caleb & Brown Provides A Tailored Approach

Benzinga

By Johnny Rice, Benzinga Sam Boyle, Senior Broker at Caleb & Brown, was recently a guest on Benzinga’s All-Access. Caleb & Brown is a crypto investor’s expert partner. As a premium broker, it provides personalized service for beginners and advanced investors alike and helps its clients navigate the sometimes turbulent waters of crypto to build wealth. Mr. Boyle spoke about the state of the market and what he sees coming in the future. Watch the interview here: Featured photo by Traxer on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:50 AM Eastern Daylight Time

Video Image

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Benzinga

By Meg Flippin, Benzinga MAIA Biotechnology Inc. (NYSE: MAIA), a clinical-stage biopharmaceutical company focused on developing and commercializing targeted immunotherapies for cancer, reported positive interim survival benefits in a phase 2 study of THIO, its lead therapy to fight advanced non-small cell lung cancer (NSCLC). NSCLC is a disease in which cancer cells form in the tissues of the lung. It’s the most common form of lung cancer in the U.S., accounting for 81% of lung cancer diagnoses. The five-year survival rate for this type of cancer is 28%. In the phase 2 clinical trial dubbed THIO-101, MAIA is evaluating THIO sequenced with Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced NSCLC who failed two or more standard-of-care therapy regimens. As of August, 16 patients had survival follow-ups surpassing 12 months, including 9 patients in their third line of treatment. Interim median survival follow-up in third-line patients was 10.6 months. Three of the trials' earliest patients enrolled are nearing 17-month survival benefits. “THIO is showing a survival benefit for patients with advanced NSCLC. We’re on track to achieve our survival goals in third-line therapy,” said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. “THIO’s outperformance to date supports our thesis that our telomere targeting agent could become a treatment option for people suffering from advanced NSCLC.” Attacking Cancer Spreading Telomeres THIO targets and attacks telomeres which play a key role in helping cancer cells live and spread. Telomerase is made from DNA sequences and proteins and sits at the end of chromosomes, capping and protecting them. Telomerase expression most often occurs in the early stages of growth and development in humans and in a few cells of adults. But in nearly all cancers, telomerase is present, allowing cancer cells to divide and spread. More than 80% of NSCLC tumors have telomerase expression. THIO induces telomerase-dependent telomeric DNA modification, DNA damage responses and selective cancer cell death. All The Data Coming Together The 12-month survival data corresponds to MAIA’s most recent data from THIO-101 demonstrating favorable disease control and overall response rates. In June, the company presented new efficacy data that showed a favorable overall response rate (ORR) of 38%, a disease control rate (DCR) of 85% and a median progression-free survival (PFS) of 5.5 months from THIO + CPI in third-line treatment. The data was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on June 3, 2024. The primary objectives of the THIO-101 phase 2 trial are to examine the safety and tolerability of THIO as an anticancer drug and as an immune system primer and to examine the clinical efficacy of THIO in the form of ORR. “All exceptional measures of efficacy in our trial to date have exceeded our own expectations and outperformed standard of care treatments,” said Vitoc when the data was released. “The data presented at ASCO advances THIO’s excellent clinical profile as a strong, safe, and highly effective alternative for patients who progressed following chemotherapy and other available treatments. We eagerly anticipate full efficacy data from THIO-101 in the second half of this year.” THIO seems to be showing promise in fighting one of the most common forms of lung cancer, but that’s not all. If this treatment proves effective, as the company believes, MAIA plans to use THIO in treating other forms of cancer, such as hepatocellular carcinoma (HCC), small cell lung cancer (SCLC) and malignant gliomas – indications to which THIO has been granted Orphan Drug Designation by the U.S. FDA. With the size of the cancer treatment market poised to hit $521 billion by 2033, growing at a CAGR of 8.9% over 2023-2033, MAIA may be one company to pay attention to. Featured photo by motorolka on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:45 AM Eastern Daylight Time

Image

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Benzinga

By Anthony Termini BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotechnology company involved in various clinical trials involving its patented approach for using stem cell therapy to treat a number of disorders. The company has, in recent months, issued updates on its earnings and operations, and it is developing a promising treatment program to treat diabetes and obesity. Quarterly Report Highlights The company issued its second quarter 2024 business update in August, and a number of announcements accompanied their reported financials. BioRestorative announced that preliminary clinical data related to its “Disc/Spine Program” showed meaningful signals and no notable safety markers in patients enrolled in a clinical study of BRTX-100 as a treatment for chronic lumbar disc disease. Also, following manufacturing/clinical process enhancements made by BioRestorative that tripled its monthly trial capacity, it guided that it was targeting completion of patient enrollment in the phase 2 BRTX-100 study in chronic lumbar disc disease (cLDD) by the end of 2024. The company also plans to provide additional preliminary data updates by then. Furthermore, BioRestorative said that it has also laid the foundation for the commercialization of its BioCosmeceuticals business, which could begin generating significant revenues this year. The company noted that it inked an agreement to supply its proprietary cell-based biologic serum to Cartessa Aesthetics, LLC. An analysis of the company’s June 30, 2024 Form 10-Q revealed a 19% improvement in year-over-year operations, with net loss narrowed to $2.5 million compared to a $3.1 million loss in the prior period. BioRestorative’s balance sheet showed some $14.7 million on hand at the end of June. Lance Alstodt, BioRestorative’s Chief Executive Officer, noted that these accomplishments “will provide additional financial flexibility” and bolster the company’s strategy to execute and accomplish important long-term goals. The quarterly report also discussed BioRestorative’s expansion of its core preclinical program for ThermoStem®. “Metabolic Program” Addresses Important And Lucrative Markets One of the more significant opportunities that BioRestorative is pursuing is related to its ThermoStem platform. Currently in preclinical testing, the intended therapy is to target obesity and metabolic disorders (like diabetes) using stem cells to generate a type of body fat that regulates metabolic homeostasis. A recent report from the Centers for Disease Control and Prevention demonstrates that nearly 42% of adults in the United States suffer from obesity. Those diagnosed with severe obesity were just over 9%. Furthermore, research conducted at Harvard University and George Washington University concluded that “adults with obesity spend an average of $1,861 more a year on medical costs than someone who doesn’t have obesity. People with severe obesity spend an average of $3,097 more.” According to investment firm Goldman Sachs, the worldwide market for obesity drugs could be $100 billion by 2030. And there is a link between obesity and diabetes. The American Heart Association says that obesity contributes to up to half of new diabetes cases annually in the United States. Treating this disease also represents a significant market opportunity for BioRestorative. Precedence Research expects the global diabetes drug market to reach about $132 billion by 2034. The combined market for obesity and diabetes drugs creates a significant opportunity for BioRestorative’s ThermoStem over the next decade. It is important to note that ThermoStem is not restricted to being only a standalone treatment. It may be used with drugs like Novo Nordisk’s (NYSE: NVO) Ozempic or Wegovy, or Eli Lilly’s (NYSE: LLY) Mounjaro, which are already approved for use to treat both obesity and diabetes. “We believe that ThermoStem has immense potential to develop both best-in-class and first-in-class therapies,” said Alstodt. Other Developments Related To BioRestorative’s Intellectual Property Portfolio Also accompanying BioRestorative’s business update announcement were comments related to its broad intellectual property portfolio. Previously published data from a study conducted at the University of Utah School of Medicine showed significant reductions in weight, triglyceride, and blood glucose levels compared to controls. The study also demonstrated that BioRestorative’s 3D scaffold was capable of retaining viable transplanted cells for at least five weeks post-implantation. In June, BioRestorative published a press release announcing that it had received notice of allowance from the Japanese Patent Office for a patent application related to ThermoStem. This is the fifth Japanese patent issued for the ThermoStem technology platform. “We are proactively expanding the already formidable ThermoStem intellectual property estate to help ensure long-term market exclusivity…” and “…this is demonstrated by this new patent allowance,” Alstodt remarked. The company also announced that it is currently involved in substantive discussions with at least one (undisclosed) regenerative medicine company regarding ThermoStem licensing. This, along with the Cartessa agreement, is why the company said that it “is poised to potentially enter into a stage of anticipated rapid growth.” Featured photo by qimono on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 11, 2024 08:35 AM Eastern Daylight Time

Image

1 ... 17 18 19 20 21 ... 3729